secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001104659-23-050654
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck Q1 revenue $14.5B (-9%), GAAP EPS $1.11; raises FY non-GAAP EPS guidance to $6.88-$7.00
--------------------------------------------------------------------------------

- Q1 revenue $14.5B, down 9% YoY; excluding LAGEVRIO and FX, up 15%.
- GAAP EPS $1.11, Non-GAAP EPS $1.40; both down 35% YoY.
- KEYTRUDA sales $5.8B (+20%), GARDASIL sales $2.0B (+35% YoY).
- LAGEVRIO sales fell 88% to $392M; proposed Prometheus acquisition for $10.8B expected Q3 2023.
- FY2023 outlook raised: sales $57.7-$58.9B, Non-GAAP EPS $6.88-$7.00; GAAP EPS lowered to $5.85-$5.97 on Zetia settlement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000110465923050654/0001104659-23-050654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000110465923050654/tm2313695d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-050654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer